Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs METAXALONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Metaxalone is a centrally acting muscle relaxant whose exact mechanism is unknown. It is thought to produce skeletal muscle relaxation by depressing the central nervous system (CNS), possibly through general CNS depression or by blocking polysynaptic reflexes in the spinal cord.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
FDA-approved: Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.,Off-label: Management of muscle spasms, spasticity.
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
800 mg orally 3 to 4 times daily
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life is approximately 0.5 to 1.5 hours, reflecting rapid clearance and supporting short-lived clinical effects.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Extensively metabolized in the liver via cytochrome P450 enzymes (CYP1A2, CYP2D6, CYP3A4, CYP2C19, and CYP2E1) to unidentified metabolites. Less than 1% excreted unchanged in urine.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug, with less than 1% eliminated in feces via biliary excretion.
38-45%, primarily bound to albumin.
Approximately 98% bound to plasma proteins, primarily albumin.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Approximately 0.3–0.5 L/kg, indicating moderate distribution into total body water and peripheral tissues.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral bioavailability is high, estimated at >80% based on urinary recovery studies.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No specific dose adjustment guidelines available; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential for accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C) as metabolism may be reduced.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Safety and efficacy not established; not recommended for use in children under 12 years of age.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Start at lower end of dosing range (e.g., 800 mg 3 times daily) due to increased sensitivity and risk of adverse effects; monitor closely.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
None.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Serotonin syndrome risk when co-administered with serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs).,Hepatic toxicity: rare reports of liver injury; use caution in patients with hepatic impairment.,CNS depressant effects: may impair mental and physical abilities; avoid concurrent alcohol or other CNS depressants.,Elderly may be more sensitive to sedative effects.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to metaxalone or any component of the formulation.,Significant hepatic impairment (e.g., severe liver disease, cirrhosis).,History of drug-induced hemolytic anemia.,Concurrent use of MAOIs or within 14 days of MAOI therapy (potential for serotonin syndrome).
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Metaxalone may be taken with or without food. Grapefruit juice may increase metaxalone levels by inhibiting CYP1A2 and CYP3A4; avoid concurrent consumption. High-fat meals may slightly delay absorption but not clinically significant.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
FDA pregnancy category C. No adequate studies in pregnant women. Animal studies have shown adverse effects (fetal resorptions, decreased fetal weight) at doses 5-10 times the human dose. Risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid; data insufficient. Second/third trimester: Limited data; may cause maternal sedation and neonatal respiratory depression if used near term.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Unknown if excreted in human milk. M/P ratio not established. Caution advised due to potential for sedation in the infant. Monitor for drowsiness, poor feeding, or weight loss. Consider alternative agents with more safety data.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No specific dose adjustments recommended due to lack of pharmacokinetic data in pregnancy. However, increased hepatic clearance during pregnancy may reduce drug levels; monitor clinical effect and adjust dose as needed. Use lowest effective dose for shortest duration.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Metaxalone is a centrally acting muscle relaxant with a unique chemical structure (oxazolidinone derivative). It is metabolized primarily by CYP1A2 and CYP2D6; caution with inhibitors or inducers of these enzymes. Onset of action is 1-2 hours; peak effect at 3-4 hours. Due to sedative properties, avoid concurrent use with alcohol or other CNS depressants. Use with caution in elderly due to anticholinergic effects and fall risk. Metaxalone is not recommended for patients with significant hepatic impairment (Child-Pugh Class C). It has no direct effect on skeletal muscle contraction but acts on CNS polysynaptic pathways.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take metaxalone exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness or dizziness; do not drive or operate heavy machinery until you know how this medication affects you.,Avoid alcohol or other sedatives while taking metaxalone as they may worsen drowsiness.,If you miss a dose, skip the missed dose and continue with your regular schedule; do not double the dose.,Contact your healthcare provider if you experience signs of an allergic reaction (rash, hives, difficulty breathing) or jaundice (yellowing of skin/eyes).,Store at room temperature, away from moisture and heat.,Do not stop abruptly; gradual dose reduction may be recommended to prevent withdrawal symptoms.
No interactions on record
"The combination of Normethadone, a μ-opioid receptor agonist with respiratory depressant effects, and Metaxalone, a centrally acting muscle relaxant that also depresses the central nervous system (CNS), results in synergistic CNS depression and respiratory depression. This can lead to profound sedation, coma, or fatal respiratory failure, particularly in patients with pre-existing respiratory compromise or those taking other CNS depressants. Concomitant use increases the risk of hypotension and bradycardia due to combined cardiorespiratory depressant effects."
"The coadministration of Metaxalone and Tiagabine may lead to increased central nervous system (CNS) depression due to additive pharmacodynamic effects. Metaxalone, a centrally acting muscle relaxant, and Tiagabine, a selective GABA reuptake inhibitor, both potentiate GABAergic activity and depress neuronal excitability. This synergism can result in enhanced sedation, dizziness, ataxia, and cognitive impairment, increasing the risk of falls and respiratory depression, especially in susceptible patients."
"Concurrent use of fluticasone propionate, a corticosteroid with immunosuppressive and anti-inflammatory properties, and metaxalone, a centrally acting muscle relaxant with sedative effects, may result in additive immunosuppression and central nervous system (CNS) depression. Corticosteroids can mask signs of infection or exacerbate existing infections, while metaxalone contributes to sedation and dizziness. This combination may increase the risk of adverse effects such as heightened sedation, impaired cognitive function, and increased susceptibility to infections, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs METAXALONE, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. METAXALONE is a Skeletal Muscle Relaxant that works by Metaxalone is a centrally acting muscle relaxant whose exact mechanism is unknown. It is thought to produce skeletal muscle relaxation by depressing the central nervous system (CNS), possibly through general CNS depression or by blocking polysynaptic reflexes in the spinal cord.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and METAXALONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of METAXALONE is: 800 mg orally 3 to 4 times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and METAXALONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. METAXALONE is classified as Category A/B. FDA pregnancy category C. No adequate studies in pregnant women. Animal studies have shown adverse effects (fetal resorptions, decreased fetal weight) at doses 5-10 times the human. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.